Quick Takeaways
- Avoro Capital Advisors LLC filed SCHEDULE 13G/A for Centessa Pharmaceuticals plc Ordinary shares, nominal value 0.002 GBP per share (CNTA).
- Disclosed ownership: 10%.
- Date of event: 31 Dec 2025.
Avoro Capital Advisors LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Centessa Pharmaceuticals plc Ordinary shares, nominal value 0.002 GBP per share (CNTA)
- Filing Manager
- Avoro Capital Advisors LLC
- Reporting Manager
- Avoro Capital Advisors LLC
- Symbol
- CNTA
- Shares outstanding
- 145,993,531 shares
- Disclosed Ownership
- 14,555,555 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 09:04:25 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Avoro Capital Advisors LLC disclosed 10% ownership in Centessa Pharmaceuticals plc Ordinary shares, nominal value 0.002 GBP per share (CNTA) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Nov 2025.
- Current filing was accepted on 17 Feb 2026, 09:04.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 10% | 14,555,555 | 14,555,555 | 0 | /s/ Scott Epstein | Scott Epstein, Chief Operating Officer and Chief Compliance Officer | |
| Behzad Aghazadeh | 10% | 14,555,555 | 14,555,555 | 0 | /s/ Behzad Aghazadeh | Behzad Aghazadeh, Individually |